Antioxidant Therapeutic Strategies for Cardiovascular Conditions Associated with Oxidative Stress

Author(s)

Farias, Jorge G. ^[1] ; Molina, Victor M. ^{[2, 3]} ; Carrasco, Rodrigo A. ^{[4, 5]} ; Zepeda, Andrea B. ^[1] ; Figueroa, Elias ^{[1, 6]} ; Letelier, Pablo ^{[1, 7]} ; Castillo, Rodrigo L. ^{[4, 8]}

Affiliation

^[1] Univ La Frontera, Fac Ingn & Ciencias, Dept Ingn Quim, Temuco 4780000 - Chile

^[2] Hosp Ninos Roberto del Rio, Unidad Cuidados Intens, Santiago 7500922 - Chile

^[3] Pontificia Univ Catolica Chile, Unidad Cuidados Intens Pediat, Hosp Clin, Santiago 7500922 - Chile

^[4] Hosp Salvador, Dept Med Interna, Lab Invest Biomed, Santiago 7500922 - Chile

^[5] Clin Alemana, Dept Cardiol, Santiago 7500922 - Chile

^[6] Univ Catolica Temuco, Nucleo Invest Prod Alimentaria, BIOACUI, Escuela Acuicultura, Temuco 4780000 - Chile

^[7] Univ Catolica Temuco, Sch Hlth Sci, Temuco 4780000 - Chile

^[8] Univ Chile, Inst Ciencias Biomed, Fac Med, Programa Fisiopatol Oriente, Santiago 7500922 - Chile

• Document type: Review article
• Source: NUTRIENTS; v. 9, n. 9 SEP 2017.
• Web of Science Citations: 35

Abstract

Oxidative stress (OS) refers to the imbalance between the generation of reactive oxygen species (ROS) and the ability to scavenge these ROS by endogenous antioxidant systems, where ROS overwhelms the antioxidant capacity. Excessive presence of ROS results in irreversible damage to cell membranes, DNA, and other cellular structures by oxidizing lipids, proteins, and nucleic acids. Oxidative stress plays a crucial role in the pathogenesis of cardiovascular diseases related to hypoxia, cardiotoxicity and ischemia-reperfusion. Here, we describe the participation of OS in the pathophysiology of cardiovascular conditions such as myocardial infarction, anthracycline cardiotoxicity and congenital heart disease. This review focuses on the different clinical events where redox factors and OS are related to cardiovascular pathophysiology, giving to support for novel pharmacological therapies such as omega 3 fatty acids, non-selective betablockers and microRNAs. (AU)